Crispr Therapeutics (CRSP)
NASDAQ:CRSP
Want to see CRSP full AI Analyst Report?
CRSP Stock Chart & Stats
$57.99
-$0.92(-2.19%)
At close: 4:00 PM EST
$57.99
-$0.92(-2.19%)
Day’s Range― - ―
52-Week Range$40.76 - $78.48
Previous CloseN/A
Volume437.82K
Average Volume (3M)1.70M
Market Cap
$4.80B
Enterprise Value$5.78B
Total Cash (Recent Filing)$2.44B
Total Debt (Recent Filing)$787.64M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Aug 10, 2026EPS Estimate
-1.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.22
Shares Outstanding96,448,790
10 Day Avg. Volume1,632,452
30 Day Avg. Volume1,696,641
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)2.45
Price to Sales (P/S)1343.50
P/FCF Ratio-13.63
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue1.41K
Enterprise Value/Gross Profit-26.29
Enterprise Value/Ebitda-10.59
Forecast
1Y Price Target
$73.85Price Target Upside27.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)-4.86
Revenue Forecast (FY)$39.04M
Bulls Say, Bears Say
Bulls Say
Strengthened Liquidity From Convertible FinancingThe $600M convertible notes materially bolstered cash reserves and extends the company’s runway, supporting ongoing late‑stage programs and commercialization activities. This durable funding reduces near‑term financing pressure and enables multi‑period clinical and commercial investments.
Sizable Equity Base On Balance SheetA strong equity cushion and moderate debt-to-equity provide solvency support for a capital‑intensive biotech. This structural strength helps absorb R&D losses, underpins ability to pursue partnerships, and preserves strategic optionality across multi‑year development cycles.
Governance And Retention Measures ApprovedBoard re‑election and an expanded incentive plan signal governance stability and improved ability to attract and retain scientific and commercial leadership. Stable management and aligned incentives support consistent execution of long‑horizon development programs.
Bears Say
Persistent Negative Cash FlowOperating cash flow remains meaningfully negative and the company continues to fund operations via reserves and financing rather than internal cash generation. Over months this increases reliance on external capital and creates execution risk if markets or funding terms tighten.
Large, Sustained Losses And Weak MarginsThe business remains far from breakeven with deeply negative margins driven by heavy R&D and development costs. Persistent losses constrain reinvestment flexibility, heighten dilution risk from future financings, and make profitable commercialization outcomes essential to long‑term viability.
Rising Leverage And Capital Structure ComplexityMaterial increase in debt, including convertibles, raises leverage and potential refinancing obligations. Convertibles add dilution risk upon conversion and complexity to capital structure, which can pressure governance choices and dilute shareholder returns if additional funding is required.
Crispr Therapeutics AG News
CRSP FAQ
What was Crispr Therapeutics’s price range in the past 12 months?
Crispr Therapeutics lowest stock price was $40.76 and its highest was $78.48 in the past 12 months.
What is Crispr Therapeutics’s market cap?
Crispr Therapeutics’s market cap is $4.80B.
When is Crispr Therapeutics’s upcoming earnings report date?
Crispr Therapeutics’s upcoming earnings report date is Aug 10, 2026 which is in 55 days.
How were Crispr Therapeutics’s earnings last quarter?
Crispr Therapeutics released its earnings results on May 04, 2026. The company reported -$1.28 earnings per share for the quarter, missing the consensus estimate of -$1.218 by -$0.062.
Is Crispr Therapeutics overvalued?
According to Wall Street analysts Crispr Therapeutics’s price is currently Undervalued.
Does Crispr Therapeutics pay dividends?
Crispr Therapeutics does not currently pay dividends.
What is Crispr Therapeutics’s EPS estimate?
Crispr Therapeutics’s EPS estimate is -1.2.
How many shares outstanding does Crispr Therapeutics have?
Crispr Therapeutics has 96,448,790 shares outstanding.
What happened to Crispr Therapeutics’s price movement after its last earnings report?
Crispr Therapeutics reported an EPS of -$1.28 in its last earnings report, missing expectations of -$1.218. Following the earnings report the stock price went down -2.24%.
Which hedge fund is a major shareholder of Crispr Therapeutics?
Currently, no hedge funds are holding shares in CRSP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Crispr Therapeutics AG Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$73.85 (27.34% Upside)
$73.85 (27.34% Upside)
Blogger Sentiment
Bullish
CRSP Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 668.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
20.63%
12-Months-Change
Fundamentals
Return on Equity
-30.88%
Trailing 12-Months
Asset Growth
25.84%
Trailing 12-Months
Company Description
Crispr Therapeutics
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
CRSP Stock 12 Month Forecast
Average Price Target
$73.85
▲(27.34% Upside)
Technical Analysis
Ownership Overview
2.54% Insiders
14.25% Mutual Funds
43.95% Other Institutional Investors
18.72% Public Companies and Individual Investors